Frontier Capital Management’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.02M Sell
187,380
-686,758
-79% -$15.8M 0.03% 278
2026
Q2
$19.4M Buy
874,138
+52,289
+6% +$972K 0.18% 189
2026
Q1
$14.9M Sell
821,849
-317,019
-28% -$5.47M 0.15% 193
2025
Q4
$22.3M Buy
1,138,868
+227,949
+25% +$4.32M 0.24% 154
2025
Q3
$11.5M Buy
910,919
+121,494
+15% +$1.39M 0.1% 235
2025
Q2
$7.52M Buy
789,425
+499,822
+173% +$5.5M 0.07% 264
2025
Q1
$3.03M Sell
289,603
-8,449
-3% -$121K 0.03% 272
2024
Q4
$7.02M Buy
+298,052
New +$8.82M 0.07% 239

Other funds holding DYN

Frontier Capital Management's DYN Position: Q3 2026 in Review

Frontier Capital Management reduced its Dyne Therapeutics (DYN) stake by 79% in Q3 2026, selling an estimated $15.8M and leaving 187,380 shares worth $3.02M. The position accounts for 0.03% of the portfolio, ranked #278.

Frontier Capital Management first reported a position in DYN in Q4 2024 and has held it in 8 quarters since. The position peaked at $22.3M in Q4 2025. 266 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Frontier Capital Management held 187,380 shares of Dyne Therapeutics worth $3.02M as of Q3 2026.
  • Frontier Capital Management sold 686,758 Dyne Therapeutics shares in Q3 2026, an estimated $15.8M.
  • Dyne Therapeutics made up 0.03% of Frontier Capital Management's portfolio in Q3 2026, its #278 holding.
  • Frontier Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Frontier Capital Management's Dyne Therapeutics position peaked at $22.3M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Frontier Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.